Ajanta Pharma informs about outcome of board meeting

31 Oct 2018 Evaluate

Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has informed that Board of Directors of Company at their meeting held on 31st October, 2018, has approved Unaudited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2018; Unaudited Standalone Financial Results of the Company for the quarter and half year ended 30th September, 2018; and Payment of interim dividend of Rs 9 (450%) per equity share on the face-value of Rs 2 per share for the Financial Year 2018-19.

The above information is a part of company’s filings submitted to BSE.

Ajanta Pharma Share Price

2638.75 12.50 (0.48%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×